Component information
No US or EU label exists for this exact combination, so information is shown for each component.
Use: Uses for the temporary relief of minor aches and pains or as recommended by your doctor. US FDA label
Use: Acute coronary syndrome – For patients with non–ST-segment elevation ACS (unstable angina [UA]/non–ST-elevation myocardial infarction [NSTEMI]), Plavix has been shown to reduce the rate of myocardial infarction (MI) and… US FDA label
Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.
Contraindications
- Severe kidney impairment (CrCl <30 mL/min)
- Severe hepatic impairment
- Active pathological bleeding
- NSAID or aspirin hypersensitivity (asthma, rhinitis, nasal polyps)
- Mastocytosis
- Third trimester of pregnancy
- Hypersensitivity
Dosing: Adult
- Acute coronary syndrome or ST-elevation myocardial infarction in patients already taking both drugs: One tablet once daily (clopidogrel 75 mg/aspirin 75 or 100 mg); duration per indication (up to 12 months after NSTE-ACS or PCI)
Dosing: Altered kidney function
The fixed combination of clopidogrel 75 mg with aspirin 75 or 100 mg is contraindicated in Europe in severe kidney impairment (creatinine clearance [CrCl] below 30 mL/min) because of the aspirin component, and experience in mild to moderate impairment is limited. Clopidogrel's antiplatelet effect is about 25% lower at CrCl 5–15 mL/min. It has no US FDA label.
Kidney function measure: European summary of product characteristics (SmPC) uses creatinine clearance (CrCl, mL/min).
Show full dosing details
- CrCl ≥60 mL/min
- Usual: one tablet once daily (clopidogrel 75 mg with aspirin 75 or 100 mg) (SmPC).
- CrCl 30–59 mL/min
- Mild to moderate impairment: limited experience; use with caution and watch for bleeding (SmPC).
- CrCl 15–29 mL/min
- Contraindicated: severe kidney impairment (CrCl <30 mL/min), because of the aspirin component (SmPC). Give clopidogrel and low-dose aspirin as separate tablets if dual therapy is needed, with specialist input.
- CrCl <15 mL/min (not on dialysis)
- Contraindicated: severe kidney impairment (CrCl <30 mL/min), because of the aspirin component (SmPC). Give clopidogrel and low-dose aspirin as separate tablets if dual therapy is needed, with specialist input.
- Hemodialysis (intermittent)
- Contraindicated as the fixed combination (severe kidney impairment). Use separate tablets if dual antiplatelet therapy is indicated; specialist input.
- Peritoneal dialysis
- Contraindicated as the fixed combination; use separate tablets if indicated.
- CRRT
- Contraindicated as the fixed combination; use separate clopidogrel and low-dose aspirin tablets if dual antiplatelet therapy is indicated.
- Dialyzable? Not stated.
- Monitoring Bleeding (especially the first month), platelet count (thrombocytopenia, thrombotic thrombocytopenic purpura), kidney function (acute kidney injury reported with pre-existing dysfunction). Stop 7 days before surgery if antiplatelet therapy must be interrupted (SmPC 4.4). If gastroprotection is needed, use pantoprazole rather than omeprazole or esomeprazole (SmPC 4.5).
Children (kidney dosing)
- eGFR ≥60
- Not established in children; kidney dosing not applicable.
- eGFR 30–59
- Not established in children; kidney dosing not applicable.
- eGFR 15–29
- Not established in children; kidney dosing not applicable.
- eGFR <15 (not on dialysis)
- Not established in children; kidney dosing not applicable.
- Hemodialysis (intermittent)
- Not established in children; kidney dosing not applicable.
- Peritoneal dialysis
- Not established in children; kidney dosing not applicable.
- CRRT
- Not established in children; kidney dosing not applicable.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
Source: EMA product information. This generic has no US FDA label.
Dosing: Pediatric
- Approved ages
- Not recommended under 18 years (SmPC).
- Usual dose
- Not established.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedDosage forms
Philippines
- Capsule: 75 mg/75 mg
- Film-coated tablet: 75 mg + 100 mg, 75 mg + 75 mg, 75 mg/100 mg, 75 mg/75 mg
- Tablet: 75 mg/75 mg
Registered products in the Philippines
10 products registered with the Food and Drug Administration (FDA) Philippines list Aspirin + Clopidogrel as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products10
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Clopel-AClopidogrel (as bisulfate) + Aspirin | 75 mg/75 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Fredun Pharmaceutical LimitedIndia | AMB HK Enterprises, Inc. | DRP-11933 | May 26, 2032 | |
Clopirin 100Clopidogrel + Aspirin | 75mg + 100mg Film-Coated TabletAlu-Alu Blister Pack x 10’s (Box of 30’s, 60’s and 100’s) | Rx | Unicure (India) Ltd.India | Despina Pharma Inc. | DRP-18940 | Oct 5, 2031 | |
Clopirin 75Clopidogrel + Aspirin | 75mg + 75mg Film-Coated TabletAlu-Alu Blister Pack x 10’s (Box of 30’s, 60’s and 100’s) | Rx | Unicure (India) Ltd.India | Despina Pharma Inc. | DRP-18939 | Oct 5, 2031 | |
ClotisprinClopidogrel (as bisulfate) + Aspirin | 75 mg/75 mg Capsule (containing Clopidogrel immediate-release pellets and Aspirin enteric-coated pellets)Alu/Alu Blister Pack x 10's Box of 100's | Rx | Pell Tech Health Care Private Ltd.India | Macropharma CorporationImporter: Ambica International Corporation | DRP-10573 | Aug 26, 2029 | |
CoplavixClopidogrel (as bisulfate) + Aspirin | 75 mg/ 100 mg Film Coated TabletAlu/Alu Blister Pack of 10's Box of 30's | Rx | Sanofi Winthrop IndustrieFrance | Importer: Sanofi-Aventis Philippines, Inc. | DR-XY41364 | Mar 11, 2030 | |
Deplatt AClopidogrel (as bisulfate) + Aspirin | 75 mg/75 mg Capsule (containing Clopidogrel immediate-release pellets and Aspirin enteric-coated pellets)Alu/Alu Blister Pack x 10's (Box of 100's) | Rx | Pell Tech Health Care Private Ltd.India | Torrent Pharma Philippines, Inc.Importer: Ambica International Corporation | DRP-10573-01 | Aug 26, 2029 | |
Ecosprin PlusClopidogrel (as bisulfate) + Aspirin | 75 mg/75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | The ACME Laboratories LimitedBangladesh | Bell-Kenz Pharma Inc.Importer: Euro Generics International Phils., Inc. | DR-XY44448 | Apr 10, 2030 | |
Norplat-SClopidogrel + Aspirin | 75 mg /75 mg TabletAlu/Alu Blister Pack x 10’s (Box of 10's) | Rx | Getz Pharma Pvt. Ltd.Pakistan | Importer: Getz Pharma (Phils.), Inc. | DR-XY39071 | Feb 9, 2027 | |
Plat-Low EAClopidogrel (as bisulfate) + Aspirin | 75 mg/75 mg CapsuleAlu/Alu Blister Pack x 10’s (Box of 100's) | Rx | Fredun Pharmaceuticals LimitedIndia | CCL Pharmaceuticals (Philippines), Inc.Importer: AMB HK Enterprises Inc. | DRP-11933-02 | May 26, 2027 | |
ValdorinClopidogrel (as bisulfate) + Aspirin | 75 mg/75 mg CapsuleAlu/Alu Blister Pack x 10’s (Box of 100’s) | Rx | Fredun Pharmaceuticals LimitedIndia | Corbridge Group Phils., Inc.Importer: AMB Hk Enterprises Inc. | DRP-11933-01 | May 26, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Omeprazole, esomeprazole | Avoid | Less clopidogrel active metabolite. | Avoid; pantoprazole has a smaller effect. |
| Oral anticoagulants | Avoid | More bleeding. | Not recommended. |
| NSAIDs including COX-2 inhibitors, SSRIs, heparin, thrombolytics, GP IIb/IIIa antagonists | Adjust or monitor | More bleeding. | Use with caution. |
| Strong CYP2C19 inducers (rifampicin); ritonavir- or cobicistat-boosted regimens | Avoid | Altered clopidogrel activation. | Avoid. |
| Methotrexate above 20 mg/week | Adjust or monitor | Aspirin lowers methotrexate clearance. | Use with caution. |
| CYP2C8 substrates (repaglinide, paclitaxel); rosuvastatin | Minor | Higher exposure (rosuvastatin about 1.4-fold). | Use with caution. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedAdverse reactions
Common
- Bleeding, bruising
- Dyspepsia, diarrhea, abdominal pain
Serious
- Gastrointestinal and intracranial bleeding
- Thrombotic thrombocytopenic purpura, aplastic anemia, agranulocytosis (rare)
- Anaphylaxis, angioedema
- Acute kidney impairment (rare, mainly with pre-existing dysfunction)
Monitoring parameters
- Bleeding (especially the first month), platelet count (thrombocytopenia, thrombotic thrombocytopenic purpura), kidney function (acute kidney injury reported with pre-existing dysfunction). Stop 7 days before surgery if antiplatelet therapy must be interrupted (SmPC 4.4). If gastroprotection is needed, use pantoprazole rather than omeprazole or esomeprazole (SmPC 4.5). Kidney
- Bleeding signs
- Platelets if symptoms
- Kidney function in CKD
Pharmacokinetics
Key PK parameters
| Half-life | Clopidogrel about 6 hours (inactive metabolite 8 hours); aspirin 0.3 to 0.4 hours; salicylic acid about 2 hours |
|---|---|
| Half-life in kidney failure (ESKD) kidney | At CrCl 5–15, clopidogrel platelet inhibition about 25% lower; bleeding time similar |
| Metabolism (CYP, transporters) | Clopidogrel: prodrug activated partly by CYP2C19; aspirin hydrolyzed to salicylic acid |
| Active metabolites | Clopidogrel thiol metabolite; salicylic acid |
| Renal excretion kidney | Clopidogrel about 50% in urine, 46% in feces (120 hours); salicylate renal excretion depends on urine pH |
| Dialyzability kidney | Not stated |
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- European Medicines Agency. DuoPlavin EPAR product information (SmPC) [EMA product information; no US FDA label]. https://www.ema.europa.eu/en/documents/product-information/duoplavin-epar-product-information_en.pdf
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- European Medicines Agency. (n.d.). DuoPlavin (clopidogrel/acetylsalicylic acid): EPAR product information [Summary of product characteristics]. Sanofi Winthrop Industrie. Retrieved November 17, 2026. https://www.ema.europa.eu/en/documents/product-information/duoplavin-epar-product-information_en.pdf
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .



